Skip to content

Use of Regional Anesthesia in Hip Arthroscopy

Use of Regional Anesthesia in Hip Arthroscopy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02851888
Enrollment
70
Registered
2016-08-02
Start date
2016-07-31
Completion date
2018-08-31
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Injuries

Brief summary

The purpose of this research is to determine differences in outcomes in patients who do, or do not, receive regional anesthesia (a fascia iliaca block) prior to undergoing hip arthroscopy with labral repair and/or debridement and osteoplasty for hip impingement

Detailed description

Patients undergoing hip arthroscopy for hip impingement at the investigator's institution often have regional anesthesia (a nerve block) prior to the procedure to help prevent and/or reduce pain following the procedure. The investigators are interested in determining benefits as well as potential adverse effects of utilizing regional anesthesia in patients undergoing hip arthroscopy for impingement. To do so, they plan to enroll patients aged 18-50 undergoing hip arthroscopy, and randomize them to one of two groups with one group receiving regional anesthesia pre-operatively and the second control group, that does not. The surgical procedure and the post-operative management will be the same for both groups. Regional anesthesia prior to orthopaedic procedures has been widely adopted in many fields of orthopaedics. While it is generally considered safe and an excellent adjuvant for pain control, there have been few studies exploring outcomes beyond pain control. In many centers, the use of regional anesthesia in hip arthroscopy is reserved for post-operative management of pain. There are multiple studies indicating that patients receiving regional anesthesia (a fascia iliaca or femoral nerve block) had significantly greater improvements in pain score and even an excellent alternative to routine narcotic medication in patients undergoing hip arthroscopy. Other orthopaedic procedures, such as knee arthroscopy, utilize similar techniques to achieve post-operative pain control through a femoral-sciatic nerve block. There have also been studies looking at the utilization of regional anesthesia via lumbar plexus blocks with hip arthroscopy. One study found that patients undergoing hip arthroscopy with higher levels of preoperative psychological distress frequently utilized a lumbar plexus block to achieve adequate pain control. Other studies found that lumbar plexus blocks significantly improved pain while in the PACU. While serious complications of lumbar plexus block were rare, minor complications such as falls, persistent paresthesias, and unexpected admissions do occur. At our institution, we do not utilize lumbar plexus blocks for regional anesthesia in patients undergoing hip arthroscopy. Rather, our standard of care is to have an anesthesiologist perform a single shot fascia iliaca block using ropivicaine while the patient is in the pre-operative holding bay. To the investigative team's knowledge, there are no studies comparing the difference in pain control, as well as the differences in narcotic requirements in PACU, duration of stay in PACU, reported falls, unplanned admissions and/or readmissions, Harris hip score and nerve pain/paresthesias/numbness in patients who have undergone hip arthroscopy with and without regional anesthesia. A better understanding of pain and functional outcomes following hip arthroscopy with and without regional anesthesia can help providers better assess circumstances when regional anesthesia can be beneficial or detrimental to a patient's post-operative course.

Interventions

DRUGRopivacaine

Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.

OTHERNormal Saline Sham Injection

Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.

PROCEDUREGeneral Anesthesia

Patients were induced and maintained in a fashion consistent with standard practices.

Sponsors

Union Memorial Hospital
CollaboratorOTHER
Georgetown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled for arthroscopic labral repair with or without osteoplasty of the hip. * 18 to 50 years old * American Society of Anesthesiologists Physical Status (ASA PS) score of I or II.

Exclusion criteria

* Current or planned pregnancy * History of neuropathic pain, chronic pain syndrome, or preoperative use of narcotic or neuropathic pain medicine * Radiographic signs of osteoarthritis (\> Tonis grade 1) * Inability to attend follow up visits * Documented allergy to local anesthetic

Design outcomes

Primary

MeasureTime frameDescription
Pain Medication Requirement in PACU24 hours post-operativelyMeasured in morphine equivalents

Secondary

MeasureTime frameDescription
Readmissions6 weekspatient reported and through chart review
Neuropathic Pain2 weeks and 6 weeksSelf Reported- Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaires will be completed at both 2 and 6 week follow-up
Time to Physical Therapy6 weekspatient reported
Duration of PACU stay (mins)24 hours post-operativelytime from PACU admission to discharge
Falls6 weekspatient reported
Long Term Pain Control (daily VAS record)6 weeksPatients will complete a daily VAS questionnaire at home
Long Term Medication Requirements (daily log of medication usage in tablets of 5 mg oxycodone, morphine extended relief 15 mg, and/or indomethacin 75 mg)6 weeksPatients will complete a daily medication log at home
Modified Harris hip score6 weeksQuestionnaire administered at 6 week follow up to evaluate functional outcomes
Visual Analogue Pain Scores (VAS)24 hours post-operativelypatient reported

Countries

United States

Contacts

Primary ContactJohn G Mawn, BS
jm2564@georgetown.edu2624883210
Backup ContactJessica B Hawken, BA
jesshawken13@gmail.com7039949605

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026